Contraindication Side Effects Nursing

Name of Drug Classification Mechanism of Action Indication

Responsibilities
Generic Name: Therapeutic Ipratropium bromide is an General Indication: -hypersensitivityto CNS: dizziness, Before:
Salbutamol + classification: anticholinergic - patients with atropine or itsderivatives. blurred vision 1. Check the doctor’s
Ipratropium Bronchodilator (parasympatholytic) agent chronic obstructive order
which, based on animal pulmonary disease Use cautiously: GI: nausea, dry 2. Assess allergy to the
Trade Name: Pharmacologic studies, appears to inhibit (COPD) on a regular -hepatic/renal mouth drug
Combivent Classification: vagally-mediated reflexes aerosol impairment. 3. Caution patient of the
Anitcholinergic by antagonizing the action bronchodilator who Respi: dyspnea, different side effects
Patient’s Dose: of acetylcholine, the continue to have Interactions : bronchospasms, 4. Obtain baseline vital
1 neb q6 Pregnancy transmitter agent released evidence of Drug-drug: horseness signs
Risk Category: at the neuromuscular bronchospasm and -Albuterol is very similar 5. Prepare drugs properly
Maximum Dose: B junctions in the lung. who require a to levalbuterol. Do not CV: palpitations, at the right dosage.
Two inhalations Anticholinergics prevent second use medications chest pain
QID the increases in bronchodilator. containing levalbuterol During:
intracellular concentration while using albuterol. 1. Verify patient’s identity
Minimum Dose: of Ca++ which is caused Patient’s -Anticholinergic agents: 2. Explain to patient the
Two inhalations by interaction of Indication: purpose of medication
QID acetylcholine with the -COPD There is potential for an 3. Advise patient to
muscarinic receptors on additive interaction with swallow medication as a
Availability: bronchial smooth muscle. concomitantly used whole
-18 mcg ipratropium anticholinergic 4. Give drug with full
bromide and 90 Salbutamol relaxes medications. glass of water to reduce
mcg albuterol bronchial, uterine, and -Beta-adrenergic agents: risk of tablet or capsule
vascular smooth muscle Caution is advised in the lodging in the esophagus.
Route: by stimulating beta 2 co-administration of 5. Do not crush, and
-Inhalation receptors. COMBIVENT Inhalation ensure that patient does
Aerosol and other not chew SR
Pharmacokinetics: sympathomimetic agents preparations.
Half life: due to the increased risk
- Salbutamol: 4 hr; of adverse cardiovascular After:
Ipratropium: 2 hr effects. 1. Monitor vital signs
Peak: -Diuretics: noting hypotension and
- Salbutamol: 2-3 hr; an irregular or abnormal
Ipratropium: 1-2 hr The ECG changes and/or pulse.
Onset: hypokalemia which may 2. Monitor for adverse
- Salbutamol: 15-30 result from the effects.
minutes; Ipratropium: 5-15 administration of non- 3. Maintain a quiet,
minutes potassium sparing comfortable environment
Duration diuretics (such as loop or to minimize anxiety and
-- Salbutamol: 4-8 hr; thiazide diuretics) can be perhaps decrease
Ipratropium: 3-6 hr acutely worsened by palpitations.
beta-agonists, especially 4. Document correctly
when the recommended and accordingly.
dose of the beta-agonist
 is exceeded.
-Monoamine oxidase
inhibitors or tricyclic
antidepressants:
administer with extreme
caution to patients being
treated with monoamine
oxidase inhibitors or
tricyclic antidepressants
or within two weeks of
discontinuation of such
agents because the
action of albuterol on the
cardiovascular system
may be potentiated.

Source: Source: Source: Source: Source: Source: Source:

Lippincott Williams Lippincott http://www.rxlist.com/com http://www.rxlist.com http://www.rxlist.com/com https://www.scribd.c https://www.scribd.com/d
& Wilkins. Williams & bivent-drug/clinical- /combivent- bivent-drug/warnings- om/doc/35220539/ oc/35220539/Drug-Study
(Producer). (2013). Wilkins. pharmacology.htm drug/warnings- precautions.htm Drug-Study
Nursing 2013 Drug (Producer). precautions.htm
Handbook. (2013). Nursing
Philadelphia, Pa.: 2013 Drug
Lippincott, Williams Handbook.
& Wilkins Philadelphia,
Pa.:
Lippincott,
Williams &
Wilkins